Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
43.2M
-
Shares change
-
-2.97M
-
Total reported value, excl. options
-
$83.3M
-
Value change
-
-$4.14M
-
Put/Call ratio
-
9.5
-
Number of buys
-
15
-
Number of sells
-
-19
-
Price
-
$1.93
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q4 2022
49 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q4 2022.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.2M shares
of 122M outstanding shares and own 35.53% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (11.4M shares), Frazier Life Sciences Management, L.P. (6.66M shares), Fairmount Funds Management LLC (5.7M shares), Rubric Capital Management LP (5.68M shares), VIKING GLOBAL INVESTORS LP (4.4M shares), VR Adviser, LLC (3.05M shares), MAI Capital Management (1.72M shares), VANGUARD GROUP INC (1.44M shares), SILVERARC CAPITAL MANAGEMENT, LLC (768K shares), and Opaleye Management Inc. (485K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.